These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23225494)

  • 1. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis.
    Qi WX; Min DL; Shen Z; Sun YJ; Lin F; Tang LN; He AN; Yao Y
    Int J Cancer; 2013 Jun; 132(12):2967-74. PubMed ID: 23225494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.
    Sonpavde G; Je Y; Schutz F; Galsky MD; Paluri R; Rosenberg JE; Bellmunt J; Choueiri TK
    Crit Rev Oncol Hematol; 2013 Jul; 87(1):80-9. PubMed ID: 23317774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Qi WX; Sun YJ; Tang LN; Shen Z; Yao Y
    Crit Rev Oncol Hematol; 2014 Mar; 89(3):394-403. PubMed ID: 24182420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis.
    Liu B; Ding F; Zhang D; Wei GH
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):487-495. PubMed ID: 28695268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Schutz FA; Je Y; Richards CJ; Choueiri TK
    J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
    Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
    Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis.
    Qi WX; Shen Z; Tang LN; Yao Y
    Crit Rev Oncol Hematol; 2014 Nov; 92(2):71-82. PubMed ID: 24878433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Ghatalia P; Morgan CJ; Je Y; Nguyen PL; Trinh QD; Choueiri TK; Sonpavde G
    Crit Rev Oncol Hematol; 2015 May; 94(2):228-37. PubMed ID: 25577572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
    Choueiri TK; Schutz FA; Je Y; Rosenberg JE; Bellmunt J
    J Clin Oncol; 2010 May; 28(13):2280-5. PubMed ID: 20351323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.
    Qi WX; Shen Z; Tang LN; Yao Y
    Br J Clin Pharmacol; 2014 Oct; 78(4):748-62. PubMed ID: 24661224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
    Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis.
    Das A; Mahapatra S; Bandyopadhyay D; Samanta S; Chakraborty S; Philpotts LL; Jahangir E; Roy B
    Crit Rev Oncol Hematol; 2021 Jan; 157():103186. PubMed ID: 33309571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.
    Petrelli F; Cabiddu M; Borgonovo K; Barni S
    Ann Oncol; 2012 Jul; 23(7):1672-9. PubMed ID: 22241897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.
    Massey PR; Okman JS; Wilkerson J; Cowen EW
    Support Care Cancer; 2015 Jun; 23(6):1827-35. PubMed ID: 25471178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis.
    Zhang ZF; Wang T; Liu LH; Guo HQ
    PLoS One; 2014; 9(3):e90135. PubMed ID: 24621598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients.
    Ding F; Liu B; Wang Y
    J Am Acad Dermatol; 2020 Sep; 83(3):788-796. PubMed ID: 30991119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.
    Sivendran S; Liu Z; Portas LJ; Yu M; Hahn N; Sonpavde G; Oh WK; Galsky MD
    Cancer Treat Rev; 2012 Nov; 38(7):919-25. PubMed ID: 22651902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials.
    Qi WX; Tang LN; Sun YJ; He AN; Lin F; Shen Z; Yao Y
    Ann Oncol; 2013 Dec; 24(12):2943-52. PubMed ID: 23921791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.
    Qi WX; He AN; Shen Z; Yao Y
    Br J Clin Pharmacol; 2013 Sep; 76(3):348-57. PubMed ID: 23617405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.
    Li J; Gu J
    Int J Clin Oncol; 2017 Oct; 22(5):807-816. PubMed ID: 28733794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.